CD19-negative relapse of pediatric B-cell precursor acute lymphoblastic leukemia following blinatumomab treatment
The result's identifiers
Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216208%3A11130%2F17%3A10374005" target="_blank" >RIV/00216208:11130/17:10374005 - isvavai.cz</a>
Alternative codes found
RIV/00064203:_____/17:10374005
Result on the web
<a href="https://doi.org/10.1038/s41408-017-0023-x" target="_blank" >https://doi.org/10.1038/s41408-017-0023-x</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.1038/s41408-017-0023-x" target="_blank" >10.1038/s41408-017-0023-x</a>
Alternative languages
Result language
angličtina
Original language name
CD19-negative relapse of pediatric B-cell precursor acute lymphoblastic leukemia following blinatumomab treatment
Original language description
CD19-negative relapse in B-cell precursor acute lymphoblastic leukemia (ALL) is observed as an infrequent event after chemotherapy and in up to 20% of patients after CD19-directed chimeric antigen receptor (CAR) T-cell immunotherapy. Patients with CD19-negative relapse usually have a poor prognosis. The mechanisms underlying CD19-negative relapse are not fully understood but are important to elucidate to further optimize CD19-directed immunotherapies. Monitoring blasts in patients with CD19-negative relapse by flow cytometry is challenging due to the lack of cell surface markers other than CD19 that are consistently expressed. Furthermore, CD19 is often used as a parameter to quantify minimal residual disease (MRD) and diagnose relapse. Potential markers to monitor persistent or recurrent leukemic blasts in an emergent CD19-negative blast population include B-cell lineage antigens (CD20, CD22, CD24, and intracellular [i]CD79a) and the common ALL antigen CD10.
Czech name
—
Czech description
—
Classification
Type
J<sub>imp</sub> - Article in a specialist periodical, which is included in the Web of Science database
CEP classification
—
OECD FORD branch
30204 - Oncology
Result continuities
Project
—
Continuities
I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace
Others
Publication year
2017
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Data specific for result type
Name of the periodical
Blood Cancer Journal
ISSN
2044-5385
e-ISSN
—
Volume of the periodical
7
Issue of the periodical within the volume
December
Country of publishing house
GB - UNITED KINGDOM
Number of pages
5
Pages from-to
—
UT code for WoS article
000418947600001
EID of the result in the Scopus database
2-s2.0-85038625175